Brookfield Asset Management (NYSE: BAM) reported Q1 EPS of ($0.20), $0.65 worse than the analyst estimate of $0.45. Revenue for the quarter came in at $16.59 billion versus the consensus estimate of $18.45 billion.

"During this challenging time, it is more important than ever to avoid hospitalization. We believe sulopenem, as potentially the first and only oral and IV penem antibiotic, will provide physicians the confidence and flexibility to treat their patients in a community setting. Should hospitalization be required, sulopenem can also be used as a step-down therapy allowing patients to leave the hospital sooner thereby reducing the risk of hospital-acquired infections, which is a benefit for patients, their families, and the over-stressed healthcare system,” said Corey Fishman, Chief Executive Officer of Iterum Therapeutics. “We expect to share topline results from our complicated urinary tract infection (cUTI) trial this month and topline results from our uncomplicated urinary tract infection (uUTI) trial shortly thereafter within the second quarter.”

For earnings history and earnings-related data on Brookfield Asset Management (BAM) click here.